Neurofibromatosis is a genetic disorder that can cause tumors in various parts of the central nervous system (CNS). There are two types of neurofibromatosis. Type 1, the more common kind, usually occurs outside of the CNS. Type 2 occurs within the CNS. Type 2 neurofibromatosis causes multiple CNS tumors, including neurofibromas, multiple meningiomas, bilateral vestibular schwannomas, optic nerve gliomas, and spinal cord tumors. Symptoms include loss of balance, tinnitus, total hearing loss, facial pain or numbness, and headache. Surgery is the standard treatment.
Severe hepatic reactions, including acute liver failure, jaundice, hepatitis, and cholestasis have been reported in patients receiving REMICADE ® postmarketing. Some cases were fatal or required liver transplant. Aminotransferase elevations were not noted prior to discovery of liver injury in many cases. Patients with symptoms or signs of liver dysfunction should be evaluated for evidence of liver injury. If jaundice and/or marked liver enzyme elevations(eg, ≥5 times the upper limit of normal) develop, REMICADE ® should be discontinued, and a thorough investigation of the abnormality should be undertaken.